Table 1 Summary of the studies on prevalence or genotype of HBV in Cambodia, 1990–2020
No | Study Period | Publication Year | First Author | Study Design | Study Population | Study Area | Grade | Diagnostic Method | Number of participants with HBV infection | Total number of participants | Genotype |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1990–1991 | 1993 | Thuring E. G | Cross-sectional | General population | Rural | Medium | Abbott, North Chicago, USA | 41 | 505 | - |
2 | 1996–1998 | 2002 | Chhour Y. M | Cross-sectional | General population | Urban | Low | AUZYME Monoclonal | 1 | 44 | - |
3 | 1997 | 2003 | Sarmati, L | Cross-sectional | General population | Rural | Low | Serodia Hbs; Fujirebio, Inc | 15 | 164 | - |
4 | 2006 | 2009 | Soeung S. C | Cross-sectional | General population | Nationwide | High | Abbott Determine test strip; Abbott Laboratories, Abbott Park, IL | 55 | 1558 | - |
5 | 2007 | 2009 | Ol H. S | Cross-sectional | General population | Rural | Medium | Monolisa® BioRad | 92 | 1200 | - |
6 | - | 2010 | Sa-Nguanmoo P | Cross-sectional | General population | Rural | Medium | Murex Biotech Limited, Dartford, Kent, England | 121 | 1119 | A = 1, B = 13, C = 86 |
7 | 2011 | 2013 | Mao B | Cross-sectional | General population | Rural/Urban | High | Alere Determineâ„¢ | 34 | 2402 | - |
8 | 2010–2012 | 2015 | Yamada H | Cross-sectional | General population | Rural | Medium | Reversed Passive hemagglutination assay (R-PHA) | 22 | 483 | - |
9 | 2011–2015 | 2018 | Fujimoto M | Pro-cohort | General population | Rural | High | Mycell II HBsAg; Tokyo Japan; Architect HBsAg QT; Abbott, Tokyo, Japan; Lumipulse; Fujirebio, Tokyo, Japan | 5 | 248 | - |
10 | 2017 | 2017 | Ork V | Cross-sectional | General population | Nationwide | High | Alere Determineâ„¢ | 103 | 4546 | - |
11 | 1997–1998 | 2000 | Ohshige K | Cross-sectional | High risk/co-infection | Rural | Medium | Serodia, Fujirebio, Tokyo, Japan | 19 | 202 | - |
12 | 2002 | 2004 | Buchy P | Cross-sectional | High risk/co-infection | Urban | Low | Monolisa HBsAg Plus® | 37 | 90 | - |
13 | 2003–2012 | 2014 | van Griensven, J | Retro-cohort | High risk/co-infection | Urban | High | Roche Diagnostics, Mannheim Germany Abbott laboratories, Illinois, US | 341 | 3098 | - |
14 | 2006–2011 | 2015 | Narin P | Cross-sectional | High risk/co-infection | Urban | Low | N/A | 113 | 209 | - |
15 | 2003–2015 | 2016 | Chassagne, F | Cross-sectional | High risk/co-infection | Urban | Medium | N/A | 221 | 511 | - |
16 | 2014–2016 | 2017 | De Weggheleire A | Cross-sectional | High risk/co-infection | Rural | Medium | Roche Diagnostics | 311 | 3045 | - |
17 | 2014–2015 | 2018 | Rouet, F | Cross-sectional | High risk/co-infection | Rural | Medium | Alere Medical Co, Chiba, Japan | 27 | 209 | - |
18 | 2016–2017 | 2019 | Nouhin, J | Pro-cohort | High risk/co-infection | Rural/Urban | High | N/A | 51 | 2548 | - |
19 | 2001–2002 | 2006 | Srey C. T | Case control | - | Urban | Medium | Abbott Laboratories, Chicago, IL, USA | - | 22 | B = 6, C = 16 |
20 | 2003 | 2008 | Huy T. T | Cross-sectional | - | Urban | Medium | axsym HBsAg | - | 12 | B = 4, C = 8 |
21 | 2010–2014 | 2019 | Chuon C | Pro-cohort | - | Rural | High | R-PHA, Mycell II HBsAg; Institute of Immunology, Tokyo Japan; Architect HBsAg QT; Abbott, Tokyo, Japan | - | 26 | B = 2, C = 24 |
22 | 2017 | 2020 | Ko K | Cross-sectional | - | Nationwide | High | LumipulseII® HBsAg, Fujirebio, Japan | - | 82 | B = 16, C = 66 |